UA80248C2 - Compounds and compositions for delivering active agents - Google Patents

Compounds and compositions for delivering active agents Download PDF

Info

Publication number: UA80248C2
Authority: UA; Ukraine
Prior art keywords: insulin; active agent; sodium; solution; compound
Prior art date: 2000-06-29

Application number

UA2003010772A

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-29

Filing date

2001-06-29

Publication date

2007-09-10

2001-06-29 Application filed filed Critical

2007-09-10 Publication of UA80248C2 publication Critical patent/UA80248C2/uk

Links

239000000203 mixture Substances 0.000 title abstract description 82
239000013543 active substance Substances 0.000 title abstract description 79
150000001875 compounds Chemical class 0.000 title abstract description 57
238000000034 method Methods 0.000 abstract description 13
238000002360 preparation method Methods 0.000 abstract description 11
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 78
239000000243 solution Substances 0.000 description 53
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
108090001061 Insulin Proteins 0.000 description 38
102000004877 Insulin Human genes 0.000 description 38
229940125396 insulin Drugs 0.000 description 38
241001465754 Metazoa Species 0.000 description 33
229960000265 cromoglicic acid Drugs 0.000 description 26
239000011541 reaction mixture Substances 0.000 description 26
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 25
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
235000002639 sodium chloride Nutrition 0.000 description 23
239000003795 chemical substances by application Substances 0.000 description 22
150000003839 salts Chemical class 0.000 description 21
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
238000006243 chemical reaction Methods 0.000 description 18
108090000765 processed proteins & peptides Proteins 0.000 description 18
102000004196 processed proteins & peptides Human genes 0.000 description 17
239000011734 sodium Substances 0.000 description 17
229910052708 sodium Inorganic materials 0.000 description 17
239000007787 solid Substances 0.000 description 17
239000002775 capsule Substances 0.000 description 16
229940124447 delivery agent Drugs 0.000 description 16
239000000122 growth hormone Substances 0.000 description 15
210000002966 serum Anatomy 0.000 description 15
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
238000002156 mixing Methods 0.000 description 13
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 12
102000014150 Interferons Human genes 0.000 description 12
108010050904 Interferons Proteins 0.000 description 12
239000002253 acid Substances 0.000 description 12
150000001413 amino acids Chemical class 0.000 description 12
210000004369 blood Anatomy 0.000 description 12
239000008280 blood Substances 0.000 description 12
229940088597 hormone Drugs 0.000 description 12
239000005556 hormone Substances 0.000 description 12
229940079322 interferon Drugs 0.000 description 12
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
238000003756 stirring Methods 0.000 description 12
239000008367 deionised water Substances 0.000 description 11
229910021641 deionized water Inorganic materials 0.000 description 11
239000003814 drug Substances 0.000 description 11
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
102000055006 Calcitonin Human genes 0.000 description 10
108060001064 Calcitonin Proteins 0.000 description 10
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 10
239000002552 dosage form Substances 0.000 description 10
239000011521 glass Substances 0.000 description 10
238000010438 heat treatment Methods 0.000 description 10
-1 polyethylene Polymers 0.000 description 10
239000000126 substance Substances 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 9
229920000669 heparin Polymers 0.000 description 9
229960002897 heparin Drugs 0.000 description 9
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 8
239000000854 Human Growth Hormone Substances 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
229960004015 calcitonin Drugs 0.000 description 8
239000012634 fragment Substances 0.000 description 8
159000000000 sodium salts Chemical class 0.000 description 8
239000007790 solid phase Substances 0.000 description 8
102000002265 Human Growth Hormone Human genes 0.000 description 7
108010000521 Human Growth Hormone Proteins 0.000 description 7
102000003982 Parathyroid hormone Human genes 0.000 description 7
108090000445 Parathyroid hormone Proteins 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000000706 filtrate Substances 0.000 description 7
239000010410 layer Substances 0.000 description 7
229910052757 nitrogen Inorganic materials 0.000 description 7
239000000199 parathyroid hormone Substances 0.000 description 7
229960001319 parathyroid hormone Drugs 0.000 description 7
229920001184 polypeptide Polymers 0.000 description 7
239000012453 solvate Substances 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
241000283690 Bos taurus Species 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
239000007864 aqueous solution Substances 0.000 description 6
229940125904 compound 1 Drugs 0.000 description 6
210000003238 esophagus Anatomy 0.000 description 6
235000013305 food Nutrition 0.000 description 6
239000007788 liquid Substances 0.000 description 6
230000036961 partial effect Effects 0.000 description 6
239000012071 phase Substances 0.000 description 6
239000008363 phosphate buffer Substances 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
206010002091 Anaesthesia Diseases 0.000 description 5
102000003951 Erythropoietin Human genes 0.000 description 5
108090000394 Erythropoietin Proteins 0.000 description 5
102000018997 Growth Hormone Human genes 0.000 description 5
108010051696 Growth Hormone Proteins 0.000 description 5
101000976075 Homo sapiens Insulin Proteins 0.000 description 5
241000700159 Rattus Species 0.000 description 5
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical group [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
229910021529 ammonia Inorganic materials 0.000 description 5
230000037005 anaesthesia Effects 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
229940105423 erythropoietin Drugs 0.000 description 5
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 5
239000000047 product Substances 0.000 description 5
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
241000282693 Cercopithecidae Species 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
239000004698 Polyethylene Substances 0.000 description 4
210000001367 artery Anatomy 0.000 description 4
230000004888 barrier function Effects 0.000 description 4
239000002585 base Substances 0.000 description 4
238000004821 distillation Methods 0.000 description 4
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000008103 glucose Substances 0.000 description 4
229960003299 ketamine Drugs 0.000 description 4
229920000573 polyethylene Polymers 0.000 description 4
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000012066 reaction slurry Substances 0.000 description 4
238000010992 reflux Methods 0.000 description 4
239000003826 tablet Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
108010036949 Cyclosporine Proteins 0.000 description 3
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101000741445 Homo sapiens Calcitonin Proteins 0.000 description 3
108010002352 Interleukin-1 Proteins 0.000 description 3
102000000589 Interleukin-1 Human genes 0.000 description 3
108010041111 Thrombopoietin Proteins 0.000 description 3
102000036693 Thrombopoietin Human genes 0.000 description 3
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 3
108010004977 Vasopressins Proteins 0.000 description 3
102000002852 Vasopressins Human genes 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
239000003637 basic solution Substances 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000011575 calcium Substances 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
229960001265 ciclosporin Drugs 0.000 description 3
229930182912 cyclosporin Natural products 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000000975 dye Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
239000002532 enzyme inhibitor Substances 0.000 description 3
239000000945 filler Substances 0.000 description 3
229940045644 human calcitonin Drugs 0.000 description 3
210000004283 incisor Anatomy 0.000 description 3
229940047124 interferons Drugs 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
125000000896 monocarboxylic acid group Chemical group 0.000 description 3
239000006186 oral dosage form Substances 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000004014 plasticizer Substances 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
238000003825 pressing Methods 0.000 description 3
230000002685 pulmonary effect Effects 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000003488 releasing hormone Substances 0.000 description 3
238000005070 sampling Methods 0.000 description 3
239000002002 slurry Substances 0.000 description 3
239000011343 solid material Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000003828 vacuum filtration Methods 0.000 description 3
229960003726 vasopressin Drugs 0.000 description 3
238000005303 weighing Methods 0.000 description 3
AMMBUJFMJOQABC-UHFFFAOYSA-N 1-carboxypropylazanium;chloride Chemical compound Cl.CCC(N)C(O)=O AMMBUJFMJOQABC-UHFFFAOYSA-N 0.000 description 2
NXRFMWBOQWRGFW-UHFFFAOYSA-N 4-chloro-2-hydroxybenzamide Chemical compound NC(=O)C1=CC=C(Cl)C=C1O NXRFMWBOQWRGFW-UHFFFAOYSA-N 0.000 description 2
LWXFCZXRFBUOOR-UHFFFAOYSA-N 4-chloro-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1O LWXFCZXRFBUOOR-UHFFFAOYSA-N 0.000 description 2
241000972773 Aulopiformes Species 0.000 description 2
101001011741 Bos taurus Insulin Proteins 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
101800000414 Corticotropin Proteins 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
108010017544 Glucosylceramidase Proteins 0.000 description 2
102000004547 Glucosylceramidase Human genes 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229920002683 Glycosaminoglycan Polymers 0.000 description 2
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
229920001499 Heparinoid Polymers 0.000 description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
102000006835 Lamins Human genes 0.000 description 2
108010047294 Lamins Proteins 0.000 description 2
102000009151 Luteinizing Hormone Human genes 0.000 description 2
108010073521 Luteinizing Hormone Proteins 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
101800000989 Oxytocin Proteins 0.000 description 2
102400000050 Oxytocin Human genes 0.000 description 2
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 2
241000288906 Primates Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
102000013275 Somatomedins Human genes 0.000 description 2
102000005157 Somatostatin Human genes 0.000 description 2
108010056088 Somatostatin Proteins 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
108010059993 Vancomycin Proteins 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
230000009102 absorption Effects 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000000654 additive Substances 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000001746 atrial effect Effects 0.000 description 2
231100000693 bioaccumulation Toxicity 0.000 description 2
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 2
239000012267 brine Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
WESLSUXBZGCBOK-UHFFFAOYSA-N butyl 4-chloro-2-hydroxybenzoate Chemical compound CCCCOC(=O)C1=CC=C(Cl)C=C1O WESLSUXBZGCBOK-UHFFFAOYSA-N 0.000 description 2
229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
229960001076 chlorpromazine Drugs 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
229960000258 corticotropin Drugs 0.000 description 2
238000011161 development Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
VSHJAJRPRRNBEK-LMVCGNDWSA-N eel calcitonin Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CS)[C@@H](C)O)C(C)C)CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C1=CN=CN1 VSHJAJRPRRNBEK-LMVCGNDWSA-N 0.000 description 2
238000000921 elemental analysis Methods 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000001914 filtration Methods 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000002554 heparinoid Substances 0.000 description 2
229940025770 heparinoids Drugs 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
210000005053 lamin Anatomy 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
229940040129 luteinizing hormone Drugs 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
229960001723 oxytocin Drugs 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000002831 pharmacologic agent Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920001308 poly(aminoacid) Polymers 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
230000011514 reflex Effects 0.000 description 2
GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
108010068072 salmon calcitonin Proteins 0.000 description 2
DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
229960000553 somatostatin Drugs 0.000 description 2
238000000527 sonication Methods 0.000 description 2
230000009747 swallowing Effects 0.000 description 2
210000004243 sweat Anatomy 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000005292 vacuum distillation Methods 0.000 description 2
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical group O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
229960003165 vancomycin Drugs 0.000 description 2
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
238000005406 washing Methods 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
NKBASRXWGAGQDP-UHFFFAOYSA-N 5-chlorosalicylic acid Chemical compound OC(=O)C1=CC(Cl)=CC=C1O NKBASRXWGAGQDP-UHFFFAOYSA-N 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N Acetylene Chemical compound C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
244000291564 Allium cepa Species 0.000 description 1
235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
208000031295 Animal disease Diseases 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
101800001288 Atrial natriuretic factor Proteins 0.000 description 1
102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
241000271566 Aves Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
101100287595 Caenorhabditis elegans kin-2 gene Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
229920002567 Chondroitin Polymers 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
244000241257 Cucumis melo Species 0.000 description 1
235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
206010012186 Delayed delivery Diseases 0.000 description 1
229920000045 Dermatan sulfate Polymers 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
240000002989 Euphorbia neriifolia Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010029961 Filgrastim Proteins 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
108700012941 GNRH1 Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
240000006240 Linum usitatissimum Species 0.000 description 1
235000004431 Linum usitatissimum Nutrition 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
102000015731 Peptide Hormones Human genes 0.000 description 1
108010038988 Peptide Hormones Proteins 0.000 description 1
241001483078 Phyto Species 0.000 description 1
108010005991 Pork Regular Insulin Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical group NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
101000993800 Sus scrofa Insulin Proteins 0.000 description 1
244000186561 Swietenia macrophylla Species 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
101150046432 Tril gene Proteins 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
XCVHLJMNYNLKBZ-UHFFFAOYSA-N [Zn]N Chemical compound [Zn]N XCVHLJMNYNLKBZ-UHFFFAOYSA-N 0.000 description 1
XJLATMLVMSFZBN-VYDXJSESSA-N actinonin Chemical compound CCCCC[C@H](CC(=O)NO)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1CO XJLATMLVMSFZBN-VYDXJSESSA-N 0.000 description 1
XJLATMLVMSFZBN-UHFFFAOYSA-N actinonine Natural products CCCCCC(CC(=O)NO)C(=O)NC(C(C)C)C(=O)N1CCCC1CO XJLATMLVMSFZBN-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940124277 aminobutyric acid Drugs 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
238000003556 assay Methods 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
239000012455 biphasic mixture Substances 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000001273 butane Substances 0.000 description 1
SOUGLODYPBMACB-UHFFFAOYSA-N butane;hydrate Chemical compound O.CCCC SOUGLODYPBMACB-UHFFFAOYSA-N 0.000 description 1
239000003990 capacitor Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
XMLNCADGRIEXPK-KUMOIWDRSA-M chembl2146143 Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(CO)C1=CC=CC=C1 XMLNCADGRIEXPK-KUMOIWDRSA-M 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
229910001916 chloryl Inorganic materials 0.000 description 1
125000000622 chloryl group Chemical group O=Cl(=O)[*] 0.000 description 1
DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940125890 compound Ia Drugs 0.000 description 1
239000002826 coolant Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
239000002274 desiccant Substances 0.000 description 1
229940061607 dibasic sodium phosphate Drugs 0.000 description 1
MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
XBPOBCXHALHJFP-UHFFFAOYSA-N ethyl 4-bromobutanoate Chemical compound CCOC(=O)CCCBr XBPOBCXHALHJFP-UHFFFAOYSA-N 0.000 description 1
229960004177 filgrastim Drugs 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
229960005051 fluostigmine Drugs 0.000 description 1
239000011888 foil Substances 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
159000000011 group IA salts Chemical class 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
102000058004 human PTH Human genes 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910003480 inorganic solid Inorganic materials 0.000 description 1
230000002608 insulinlike Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000003055 low molecular weight heparin Substances 0.000 description 1
229940127215 low-molecular weight heparin Drugs 0.000 description 1
KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
229960005375 lutein Drugs 0.000 description 1
ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
235000012680 lutein Nutrition 0.000 description 1
239000001656 lutein Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
239000002052 molecular layer Substances 0.000 description 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
230000001452 natriuretic effect Effects 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000000849 parathyroid Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
239000007793 ph indicator Substances 0.000 description 1
CEYGNZMCCVVXQW-UHFFFAOYSA-N phosphoric acid;propane-1,2-diol Chemical compound CC(O)CO.OP(O)(O)=O CEYGNZMCCVVXQW-UHFFFAOYSA-N 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
IMYBWPUHVYRSJG-UHFFFAOYSA-M potassium;2-aminoethanesulfonate Chemical compound [K+].NCCS([O-])(=O)=O IMYBWPUHVYRSJG-UHFFFAOYSA-M 0.000 description 1
238000012545 processing Methods 0.000 description 1
229960003598 promazine Drugs 0.000 description 1
ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
238000010926 purge Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000001223 reverse osmosis Methods 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
229960000581 salicylamide Drugs 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
229910001948 sodium oxide Inorganic materials 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
235000019640 taste Nutrition 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000009210 therapy by ultrasound Methods 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
238000012546 transfer Methods 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical class C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

UA2003010772A 2000-06-29 2001-06-29 Compounds and compositions for delivering active agents UA80248C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US21489300P	2000-06-29	2000-06-29
PCT/US2001/021073 WO2002002509A1 (en)	2000-06-29	2001-06-29	Compounds and compositions for delivering active agents

Publications (1)

Publication Number	Publication Date
UA80248C2 true UA80248C2 (en)	2007-09-10

Family

ID=22800813

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2003010772A UA80248C2 (en)	2000-06-29	2001-06-29	Compounds and compositions for delivering active agents

Country Status (24)

Country	Link
US (1)	US7351741B2 (ru)
EP (1)	EP1299348B1 (ru)
JP (1)	JP2004521857A (ru)
KR (1)	KR100828668B1 (ru)
CN (1)	CN100482637C (ru)
AT (1)	ATE391708T1 (ru)
AU (3)	AU2001273153B2 (ru)
BR (1)	BR0112311A (ru)
CA (1)	CA2411754C (ru)
CY (1)	CY1108532T1 (ru)
CZ (1)	CZ303736B6 (ru)
DE (1)	DE60133555T2 (ru)
DK (1)	DK1299348T3 (ru)
ES (1)	ES2306719T3 (ru)
HK (1)	HK1054918A1 (ru)
IL (1)	IL153297A0 (ru)
MX (1)	MXPA02012855A (ru)
NZ (1)	NZ523017A (ru)
PT (1)	PT1299348E (ru)
RU (1)	RU2326110C2 (ru)
SK (1)	SK1182003A3 (ru)
UA (1)	UA80248C2 (ru)
WO (1)	WO2002002509A1 (ru)
ZA (1)	ZA200209946B (ru)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6358504B1 (en) *	1997-02-07	2002-03-19	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US7495030B2 (en) *	2000-09-06	2009-02-24	Emisphere Technologies, Inc.	(5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
JP5196701B2 (ja)	2001-11-29	2013-05-15	エミスフィアーテクノロジーズインコーポレイテッド	クロモリンナトリウムの経口投与用製剤
US20030198666A1 (en)	2002-01-07	2003-10-23	Richat Abbas	Oral insulin therapy
EP2272501B1 (en)	2002-01-09	2013-03-20	Emisphere Technologies, Inc.	Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate
EP1478233B1 (en)	2002-02-20	2016-11-09	Emisphere Technologies, Inc.	Method for administering glp-1 molecules
US7384914B2 (en)	2003-01-06	2008-06-10	Emisphere Technologies, Inc.	Night-time oral insulin therapy
JP2006519881A (ja) *	2003-03-06	2006-08-31	エミスフィアーテクノロジーズインコーポレイテッド	経口インスリン治療及びプロトコール
EP1605895A4 (en) *	2003-03-06	2011-08-24	Emisphere Tech Inc	ORAL INSULIN THERAPY AND PROTOCOL
US7318925B2 (en) *	2003-08-08	2008-01-15	Amgen Fremont, Inc.	Methods of use for antibodies against parathyroid hormone
BR0318454A (pt)	2003-08-08	2006-09-12	Abgenix Inc	anticorpos dirigidos a hormÈnio da paratireóide (pth) e seus usos
EP1658273B1 (en)	2003-08-20	2007-01-03	Eli Lilly And Company	Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
DE602004006279T2 (de)	2003-08-20	2007-12-27	Eli Lilly And Co., Indianapolis	Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagonartigen peptid (glp)-1-verbindung oder eines melanocortin-4-rezeptor-(mc4-)agonistschen peptids
US20050203001A1 (en)	2004-03-05	2005-09-15	Emisphere Technologies, Inc.	Oral insulin therapies and protocol
CA2540172A1 (en) *	2003-09-25	2005-03-31	Cangene Corporation	Liquid human growth hormone formulation containing polyethylene glycol
US20060286129A1 (en)	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
BRPI0510226A (pt)	2004-05-06	2007-10-23	Emisphere Tech Inc	composição farmacêutica sólida, forma de dosagem sólida, método para administrar heparina a um animal, método para tratar ou evitar trombose em um animal, método para preparar uma forma de dosagem sólida de heparina umidecida
EP1745004B8 (en)	2004-05-14	2016-07-27	Emisphere Technologies, Inc.	Aryl ketone compounds and compositions for delivering active agents
US8273794B2 (en) *	2004-05-14	2012-09-25	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
AU2005244985B2 (en)	2004-05-19	2011-09-01	Emisphere Technologies, Inc.	Acyclovir formulations
CN1968704B (zh)	2004-05-19	2010-12-08	爱密斯菲尔科技公司	局部用色甘酸制剂
AU2005271526B2 (en) *	2004-08-03	2011-12-08	Emisphere Technologies, Inc.	Antidiabetic oral insulin-biguanide combination
JP4636839B2 (ja) *	2004-09-24	2011-02-23	パナソニック株式会社	電子デバイス
GB0427603D0 (en) *	2004-12-16	2005-01-19	Novartis Ag	Organic compounds
GB0427600D0 (en) *	2004-12-16	2005-01-19	Novartis Ag	Organic compounds
EP1830831B1 (en)	2004-12-29	2015-01-21	Emisphere Technologies, Inc.	Pharmaceutical formulations of gallium salts
WO2006076692A1 (en) *	2005-01-12	2006-07-20	Emisphere Technologies, Inc.	Compositions for buccal delivery of parathyroid hormone
WO2007011958A2 (en)	2005-07-15	2007-01-25	Emisphere Technologies, Inc.	Intraoral dosage forms of glucagon
CA2626029A1 (en) *	2005-11-04	2007-05-18	Genta Incorporated	Pharmaceutical gallium compositions and methods
WO2007121318A2 (en)	2006-04-12	2007-10-25	Emisphere Technologies, Inc.	Formulations for delivering insulin
WO2007133944A2 (en)	2006-05-09	2007-11-22	Emisphere Technologies, Inc.	Topical administration of acyclovir
WO2008003050A2 (en)	2006-06-28	2008-01-03	Emisphere Technologies, Inc.	Gallium nitrate formulations
CA2662853C (en)	2006-08-31	2016-07-26	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
PL2134351T3 (pl)	2007-03-13	2017-10-31	Jds Therapeutics Llc	Sposoby i kompozycje do przedłużonego uwalniania chromu
WO2009002867A2 (en)	2007-06-26	2008-12-31	Nutrition 21, Inc.	Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
CA3014633C (en) *	2007-10-08	2022-05-17	Aurinia Pharmaceuticals Inc.	Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
IL188647A0 (en) *	2008-01-08	2008-11-03	Orina Gribova	Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
WO2010021752A1 (en)	2008-08-21	2010-02-25	Alvine Pharmaceuticals, Inc.	Formulation for oral administration of proteins
AU2010259184B2 (en) *	2009-06-09	2015-08-13	Aurinia Pharmaceuticals Inc.	Topical drug delivery systems for ophthalmic use
CN105997864A (zh)	2009-07-09	2016-10-12	奥莎迪药品管理有限公司	基质载体组合物、方法及用途
EP2461803B1 (en)	2009-08-03	2018-10-17	Emisphere Technologies, Inc.	Fast-acting naproxen composition with reduced gastrointestinal effects
US20110177147A1 (en) *	2010-01-21	2011-07-21	General Electric Company	Stable biocidal delivery systems
BR112012020185A2 (pt) *	2010-02-04	2017-07-04	Lowell Parsons C	uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
JP5894726B2 (ja) *	2010-07-13	2016-03-30	株式会社大塚製薬工場	膵島の分離方法および膵島組織を保護するための保護液
KR101836957B1 (ko)	2011-03-01	2018-03-09	제이디에스 테라퓨틱스, 엘엘씨	당뇨병, 저혈당 및 관련 장애를 치료 및 예방하기 위한 인슐린과 크롬을 포함하는 조성물
RU2495866C1 (ru) *	2012-06-19	2013-10-20	Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации	Производное гамма-аминомасляной кислоты, обладающее ноотропной активностью в сочетании с транквилизирующим действием
RU2495867C1 (ru) *	2012-07-11	2013-10-20	Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации"	Дилитиевая соль n-салицилоилглицина, обладающая ноотропной активностью
PL2897620T3 (pl)	2012-09-21	2020-11-02	Intensity Therapeutics, Inc	Sposób leczenia nowotworu złośliwego
CA3216501A1 (en)	2013-04-29	2014-11-06	Memorial Sloan Kettering Cancer Center	Compositions and methods for altering second messenger signaling
WO2017139337A1 (en)	2016-02-11	2017-08-17	Nutrition 21, Llc	Chromium containing compositions for improving health and fitness
RU2633769C1 (ru) *	2016-05-16	2017-10-18	Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ГБОУ ВПО ВолгГМУ МЗ РФ	Гамма-(N-гидроксибензоиламино)бутирохлориды, как полупродукты для получения потенциальных биологически активных производных гамма-аминомасляной кислоты
US20190224275A1 (en)	2017-05-12	2019-07-25	Aurinia Pharmaceuticals Inc.	Protocol for treatment of lupus nephritis
CN108689876B (zh) *	2018-06-28	2020-11-27	苏州东南药业股份有限公司	一种8-(2-羟基苯甲酰胺基)辛酸钠的制备方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR4446E (fr)	1904-07-05	1905-08-25	Jacques Pinatel	Étau serrant les pièces coniques
US3489793A (en) *	1966-05-16	1970-01-13	Francia Formaceutici S R L	New benzamido butyric acid derivatives
ES369853A1 (es)	1969-07-24	1971-07-16	Bama S A Lab	Procedimiento para la obtencion de derivados del acido ep- silon-amino-caproico.
DE2260118C2 (de) *	1972-12-08	1982-06-03	Bayer Ag, 5090 Leverkusen	Penicilline sowie ihre Verwendung als Arzneimittel
DE2517229A1 (de) *	1975-04-18	1976-10-28	Boehringer Mannheim Gmbh	Phenylalkylcarbonsaeure-derivate und verfahren zu ihrer herstellung
NZ196349A (en)	1980-03-07	1984-08-24	Interx Research Corp	Enhancement of absorption rate of orally administered polar bioactive agents
US4442090A (en) *	1980-11-09	1984-04-10	Kyoto Yakuhin Kogyo Kabushiki Kaisha	Absorption-promoting compounds, compositions thereof with pharmaceuticals and/or bases for rectal administration and method of use
US4900730A (en) *	1981-01-14	1990-02-13	Toyo Jozo Co., Ltd.	Preparation which promotes the absorption of peptides
GB2092136B (en) *	1981-01-17	1985-06-05	Mitsui Toatsu Chemicals	Production of n-substituted amide compounds
JPS58140026A (ja) *	1982-01-14	1983-08-19	Toyo Jozo Co Ltd	吸収性良好な製剤
FR2509175B1 (fr)	1981-03-06	1987-01-16	Toyo Jozo Kk	Preparation therapeutique ayant d'excellentes proprietes d'absorption
DE3266360D1 (en) *	1981-06-16	1985-10-24	Choay Sa	Medicines containing as active ingredients compounds of the arylbenzenesulfonamide-type, and processes for their preparation
JPS611651A (ja) *	1984-06-12	1986-01-07	Toyama Chem Co Ltd	Ｎ−アシル酸性アミノ酸ジアミド類およびその製造法並びにそれらを含有する抗潰瘍剤
US4757066A (en) *	1984-10-15	1988-07-12	Sankyo Company Limited	Composition containing a penem or carbapenem antibiotic and the use of the same
LU86258A1 (fr) *	1986-01-21	1987-09-03	Rech Dermatologiques C I R D S	Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
USRE35862E (en) *	1986-08-18	1998-07-28	Emisphere Technologies, Inc.	Delivery systems for pharmacological agents encapsulated with proteinoids
FR2636238B1 (fr) *	1988-09-14	1994-01-21	Morelle Jean	Nouvelles compositions antisudorales
JPH02239980A (ja)	1989-03-15	1990-09-21	Fuji Photo Film Co Ltd	感熱記録材料
US5714167A (en) *	1992-06-15	1998-02-03	Emisphere Technologies, Inc.	Active agent transport systems
US5447728A (en) *	1992-06-15	1995-09-05	Emisphere Technologies, Inc.	Desferrioxamine oral delivery system
US5629020A (en) *	1994-04-22	1997-05-13	Emisphere Technologies, Inc.	Modified amino acids for drug delivery
US6221367B1 (en) *	1992-06-15	2001-04-24	Emisphere Technologies, Inc.	Active agent transport systems
US5443841A (en) *	1992-06-15	1995-08-22	Emisphere Technologies, Inc.	Proteinoid microspheres and methods for preparation and use thereof
US5541155A (en)	1994-04-22	1996-07-30	Emisphere Technologies, Inc.	Acids and acid salts and their use in delivery systems
US5451410A (en) *	1993-04-22	1995-09-19	Emisphere Technologies, Inc.	Modified amino acids for encapsulating active agents
US6099856A (en)	1992-06-15	2000-08-08	Emisphere Technologies, Inc.	Active agent transport systems
US5811127A (en) *	1992-06-15	1998-09-22	Emisphere Technologies, Inc.	Desferrioxamine oral delivery system
HU211995B (en)	1992-06-30	1996-01-29	Gyogyszerkutato Intezet	Process to prepare novel benzoyl amino acid derivs. and pharmaceutical compns. contg.them
US5583020A (en)	1992-11-24	1996-12-10	Ribozyme Pharmaceuticals, Inc.	Permeability enhancers for negatively charged polynucleotides
US5401516A (en) *	1992-12-21	1995-03-28	Emisphere Technologies, Inc.	Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US5958457A (en)	1993-04-22	1999-09-28	Emisphere Technologies, Inc.	Compositions for the delivery of antigens
US6610329B2 (en) *	1993-04-22	2003-08-26	Emisphere Technologies Inc.	Compositions for the delivery of antigens
US20010003001A1 (en) *	1993-04-22	2001-06-07	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5643957A (en) *	1993-04-22	1997-07-01	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5709861A (en)	1993-04-22	1998-01-20	Emisphere Technologies, Inc.	Compositions for the delivery of antigens
EP1025840B1 (en) *	1993-04-22	2005-06-29	Emisphere Technologies, Inc.	Oral drug compositions
US5935610A (en) *	1993-08-26	1999-08-10	Mclean; Linsey	Composition having buffering properties
IL115693A (en) *	1994-10-25	2000-08-13	Revlon Consumer Prod Corp	Cosmetic compositions with improved transfer resistance
US5650386A (en) *	1995-03-31	1997-07-22	Emisphere Technologies, Inc.	Compositions for oral delivery of active agents
US5989539A (en) *	1995-03-31	1999-11-23	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6090958A (en) *	1995-03-31	2000-07-18	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6001347A (en) *	1995-03-31	1999-12-14	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5866536A (en) *	1995-03-31	1999-02-02	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
CN1151836C (zh) *	1995-03-31	2004-06-02	艾米斯菲尔技术有限公司	用作传送活性剂的化合物和组合物
DE19681560T1 (de)	1995-09-11	1998-08-20	Emisphere Tech Inc	Verfahren zur Herstellung von omega-Aminoalkansäure-Derivaten aus Cycloalkanonen
SI9720025A (sl)	1996-03-29	1999-08-31	Emishphere Technologies, Inc.	Spojine in sestavki za prenos aktivne snovi
IL118657A0 (en)	1996-06-14	1996-10-16	Arad Dorit	Inhibitors for picornavirus proteases
WO1998021951A1 (en)	1996-11-18	1998-05-28	Emisphere Technologies, Inc.	Methods and compositions for inducing oral tolerance in mammals
US6358504B1 (en) *	1997-02-07	2002-03-19	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6313088B1 (en) *	1997-02-07	2001-11-06	Emisphere Technologies, Inc.	8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US5773647A (en) *	1997-02-07	1998-06-30	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6060513A (en) *	1997-02-07	2000-05-09	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6051561A (en) *	1997-02-07	2000-04-18	Emisphere Technologies Inc.	Compounds and compositions for delivering active agents
US5876710A (en) *	1997-02-07	1999-03-02	Emisphere Technologies Inc.	Compounds and compositions for delivering active agents
US5879681A (en) *	1997-02-07	1999-03-09	Emisphere Technolgies Inc.	Compounds and compositions for delivering active agents
US5804688A (en) *	1997-02-07	1998-09-08	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
ES2263428T3 (es) *	1997-02-07	2006-12-16	Emisphere Technologies, Inc.	Compuesto y composicion para agentes activos de administracion.
US5939381A (en) *	1997-02-07	1999-08-17	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5776888A (en) *	1997-02-07	1998-07-07	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5990166A (en) *	1997-02-07	1999-11-23	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5863944A (en) *	1997-04-30	1999-01-26	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5962710A (en) *	1997-05-09	1999-10-05	Emisphere Technologies, Inc.	Method of preparing salicyloylamino acids
US6440929B1 (en) *	1998-07-27	2002-08-27	Emisphere Technologies, Inc.	Pulmonary delivery of active agents
JP5144861B2 (ja) *	1998-07-27	2013-02-13	エミスフェアー・テクノロジーズ・インク	活性剤のデリバリーのための化合物及び組成物
JP4430235B2 (ja) *	1998-08-07	2010-03-10	エミスフェアー・テクノロジーズ・インク	活性剤のデリバリーのための化合物及び組成物
AU3581300A (en) *	1999-01-08	2000-07-24	Emisphere Technologies, Inc.	Polymeric delivery agents and delivery agent compounds
DE60023841T2 (de) *	1999-02-05	2006-05-24	Emisphere Technologies, Inc.	Verfahren zur herstellung alkylierter salicylamide
WO2000050386A1 (en) *	1999-02-26	2000-08-31	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
JP4850379B2 (ja) *	1999-12-16	2012-01-11	エミスフェアー・テクノロジーズ・インク	活性剤を輸送するための化合物及び組成物
US6384278B1 (en) *	2000-02-04	2002-05-07	Emisphere Technologies, Inc.	Boron-mediated amidation of carboxylic acids
US7495030B2 (en)	2000-09-06	2009-02-24	Emisphere Technologies, Inc.	(5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2004080954A1 (en) *	2003-03-11	2004-09-23	Pharmacia Corporation	S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate form ii crystalline salt

2001
- 2001-06-29 WO PCT/US2001/021073 patent/WO2002002509A1/en active IP Right Grant
- 2001-06-29 DK DK01952394T patent/DK1299348T3/da active
- 2001-06-29 US US10/312,703 patent/US7351741B2/en not_active Expired - Lifetime
- 2001-06-29 UA UA2003010772A patent/UA80248C2/uk unknown
- 2001-06-29 IL IL15329701A patent/IL153297A0/xx unknown
- 2001-06-29 CN CNB018119182A patent/CN100482637C/zh not_active Expired - Lifetime
- 2001-06-29 EP EP01952394A patent/EP1299348B1/en not_active Expired - Lifetime
- 2001-06-29 JP JP2002507766A patent/JP2004521857A/ja active Pending
- 2001-06-29 AT AT01952394T patent/ATE391708T1/de active
- 2001-06-29 DE DE60133555T patent/DE60133555T2/de not_active Expired - Lifetime
- 2001-06-29 AU AU2001273153A patent/AU2001273153B2/en not_active Ceased
- 2001-06-29 PT PT01952394T patent/PT1299348E/pt unknown
- 2001-06-29 AU AU7315301A patent/AU7315301A/xx active Pending
- 2001-06-29 CZ CZ20030275A patent/CZ303736B6/cs not_active IP Right Cessation
- 2001-06-29 BR BR0112311-4A patent/BR0112311A/pt active Search and Examination
- 2001-06-29 MX MXPA02012855A patent/MXPA02012855A/es active IP Right Grant
- 2001-06-29 SK SK118-2003A patent/SK1182003A3/sk unknown
- 2001-06-29 RU RU2003102615/04A patent/RU2326110C2/ru not_active IP Right Cessation
- 2001-06-29 CA CA002411754A patent/CA2411754C/en not_active Expired - Lifetime
- 2001-06-29 KR KR1020027017966A patent/KR100828668B1/ko not_active IP Right Cessation
- 2001-06-29 ES ES01952394T patent/ES2306719T3/es not_active Expired - Lifetime
- 2001-06-29 NZ NZ523017A patent/NZ523017A/en not_active IP Right Cessation
2002
- 2002-12-09 ZA ZA200209946A patent/ZA200209946B/en unknown
2003
- 2003-10-06 HK HK03107183A patent/HK1054918A1/xx not_active IP Right Cessation
2006
- 2006-02-17 AU AU2006200678A patent/AU2006200678B2/en not_active Ceased
2008
- 2008-06-19 CY CY20081100654T patent/CY1108532T1/el unknown

Also Published As

Publication number	Publication date
CA2411754C (en)	2009-05-26
DE60133555D1 (de)	2008-05-21
ZA200209946B (en)	2003-11-07
EP1299348B1 (en)	2008-04-09
HK1054918A1 (en)	2003-12-19
SK1182003A3 (en)	2003-09-11
JP2004521857A (ja)	2004-07-22
MXPA02012855A (es)	2004-04-20
CN1460100A (zh)	2003-12-03
PT1299348E (pt)	2008-05-12
EP1299348A1 (en)	2003-04-09
US7351741B2 (en)	2008-04-01
AU2006200678B2 (en)	2009-01-15
CY1108532T1 (el)	2014-04-09
IL153297A0 (en)	2003-07-06
CN100482637C (zh)	2009-04-29
EP1299348A4 (en)	2005-07-20
AU2001273153B2 (en)	2005-11-17
KR100828668B1 (ko)	2008-05-09
CZ303736B6 (cs)	2013-04-17
BR0112311A (pt)	2003-09-02
RU2326110C2 (ru)	2008-06-10
CA2411754A1 (en)	2002-01-10
AU2006200678A1 (en)	2006-03-09
ATE391708T1 (de)	2008-04-15
WO2002002509A1 (en)	2002-01-10
NZ523017A (en)	2004-10-29
DE60133555T2 (de)	2008-09-18
AU7315301A (en)	2002-01-14
US20040048777A1 (en)	2004-03-11
DK1299348T3 (da)	2008-07-28
ES2306719T3 (es)	2008-11-16
AU2001273153C1 (en)	2002-01-14
AU2001273153A2 (en)	2002-01-14
KR20030058958A (ko)	2003-07-07

Publication	Publication Date	Title
UA80248C2 (en)	2007-09-10	Compounds and compositions for delivering active agents
JP5144861B2 (ja)	2013-02-13	活性剤のデリバリーのための化合物及び組成物
ES2267283T3 (es)	2007-03-01	Compuestos y composiciones para la administracion de agentes activos.
US7893297B2 (en)	2011-02-22	Amorphous sodium 4-[4-chloro-2-hydroxybenzoyl)amino]butanoate
JP5089845B2 (ja)	2012-12-05	シアノフェノキシカルボン酸化合物および活性薬剤送達用組成物
ES2251976T3 (es)	2006-05-16	Compuestos y composiciones de oxadiazol para aportar agentes activos.
AU2001273153A1 (en)	2002-04-11	Compounds and compositions for delivering active agents
MXPA02004092A (es)	2003-02-12	Compuestos y composiciones de acido fenilaminocarboxilico para administrar agentes activos.
MXPA06013251A (es)	2007-02-28	Compuestos y composiciones de aril-cetona para suministrar agentes activos.
US7084279B1 (en)	2006-08-01	Oxadiazole compounds and compositions for delivering active agents
IL153297A (en)	2010-04-29	Compounds and compositions for delivering active agents